Welcome to our dedicated page for Maximus SEC filings (Ticker: MMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Maximus runs large-scale health, welfare-to-work, and technology contracts for governments worldwide; that mix of service lines makes its SEC disclosures anything but straightforward. If you’ve ever searched “Where can I read the Maximus quarterly earnings report 10-Q filing?” or tried to decode revenue by segment in the annual 10-K, you know the challenge.
Stock Titan solves that complexity. Our AI engine scans every Maximus SEC filing the instant it hits EDGAR—whether it’s a Form 8-K announcing a new Medicaid contract or the proxy statement detailing executive compensation. You’ll see AI-powered summaries that turn legal prose into plain language, answering queries like “Maximus 8-K material events explained,” “understanding Maximus SEC documents with AI,” and delivering Maximus insider trading Form 4 transactions in real time.
- 10-K – Maximus annual report 10-K simplified with backlog and segment margin breakdowns.
- 10-Q – Maximus earnings report filing analysis that compares quarter-over-quarter trends.
- Form 4 – Maximus Form 4 insider transactions real-time for tracking executive stock activity.
- 8-K – Material contract wins and amendments distilled in minutes.
- DEF 14A – Maximus proxy statement executive compensation laid out clearly.
Whether you’re screening for cash-flow swings, monitoring “Maximus executive stock transactions Form 4,” or simply want “Maximus SEC filings explained simply,” our expert analysis, AI-generated highlights, and continuous updates deliver the insights you need—without wading through hundreds of pages.
MAXIMUS, Inc. announced an increase to its existing stock purchase program and said it intends to buy shares opportunistically in the open market, under 10b5-1 plans, or via privately negotiated transactions. The company specified the program has no set purchase amount or expiration date and may be extended, modified, suspended or discontinued at its discretion. A press release describing the increase is filed as Exhibit 99.1 to this Current Report. The filing includes standard forward-looking statements language and points investors to the company’s Annual Report for additional risk factors and disclosures.
Anne K. Altman, a director of MAXIMUS, Inc. (MMS), reported an acquisition on 08/31/2025 of dividend equivalent rights tied to previously awarded restricted stock units. The filing shows 10.491 dividend-equivalent shares were acquired at $0, and the reporting person now beneficially owns 32,055.435 shares (direct ownership). The filing explains these dividend equivalents vest proportionately with the underlying RSUs and are the economic equivalent of one share each. The form was signed by an attorney-in-fact on 09/03/2025.
Ilene Baylinson, General Manager - Health & Human at MAXIMUS, Inc. (MMS), received dividend equivalent rights on 08/31/2025 that converted to the economic equivalent of 129.906 shares of MAXIMUS common stock. These rights accrue alongside previously awarded restricted stock units and certain performance share units where performance criteria were met. Following the reported accrual, Ms. Baylinson beneficially owns 38,201.195 shares, held directly. The Form 4 was signed by an attorney-in-fact on 09/03/2025. The filing discloses a routine equity accrual tied to awards rather than an open-market trade or option exercise.
Bruce Caswell, CEO & President and a director of MAXIMUS, Inc. (MMS), reported on Form 4 that on 08/31/2025 he acquired 807.268 shares of MAXIMUS common stock as dividend equivalent rights that accrued on previously awarded restricted stock units and certain performance share units. The transaction price is reported as $0. After the transaction, he beneficially owned 237,390.466 shares, held directly. The filing was signed by an attorney-in-fact on 09/03/2025. The form explains each dividend equivalent right is the economic equivalent of one share of MAXIMUS common stock.
Theresa D. Golinvaux, Principal Accounting Officer of MAXIMUS, Inc. (MMS), reported a non‑derivative acquisition tied to dividend equivalent rights on 08/31/2025. The filing shows 33.091 dividend-equivalent shares were added (priced at $0) that relate to previously awarded restricted stock units and certain performance share units whose performance criteria were met. After this accrual, the reporting person beneficially owns 9,731.152 shares of MAXIMUS common stock. The transaction reflects compensation-related equity accruals rather than open-market trading.
Michelle Link, Chief of Human Resources and officer of MAXIMUS, Inc. (MMS), received 97.051 shares as dividend equivalent rights related to previously awarded restricted stock units and performance share units. These dividend equivalent rights are the economic equivalent of one share of MAXIMUS common stock each and vest proportionately with the underlying RSUs and vested PSUs where performance criteria were met. After the reported accrual, Ms. Link beneficially owns 28,539.482 shares of MAXIMUS common stock, held directly.
Jan Madsen, a director of MAXIMUS, Inc. (MMS), received dividend equivalent rights tied to previously awarded restricted stock units that converted into 49.475 shares on 08/31/2025 at no cash cost, increasing his reported beneficial ownership to 18,206.463 shares. The filing identifies the acquisition as dividend equivalents that vest proportionately with the underlying RSUs, rather than a market purchase. The Form 4 was signed on behalf of Madsen by an attorney-in-fact, John T Martinez, on 09/03/2025. This disclosure reflects an insider non-cash award accrual, not a cash transaction or option exercise.
Insider transaction at MAXIMUS, Inc. (MMS): On 08/31/2025 John J. Haley, a company director, reported the acquisition of 102.761 dividend-equivalent rights related to previously awarded restricted stock units, recorded at a $0 price. Following this transaction Mr. Haley is shown as beneficially owning 39,867.345 shares directly and 71,132 shares indirectly through the John J. Haley Grantor Retained Annuity Trust Seven and 32,764 shares indirectly through the John J. Haley Grantor Retained Annuity Trust Six. The filing was signed by an attorney-in-fact on 09/03/2025.
John T. Martinez, Chief Legal Officer of MAXIMUS, Inc. (MMS), reported a transaction dated 08/31/2025 on Form 4 showing the acquisition of 144.404 shares of common stock through dividend equivalent rights that accrued on previously awarded restricted stock units (RSUs) and certain performance share units (PSUs). The dividend equivalents vest proportionately with the underlying RSUs/PSUs and each right is economically equivalent to one share. The report lists 33,642.02 shares of common stock beneficially owned following the transaction and indicates the acquisition price as $0, reflecting in-kind dividend equivalence rather than a market purchase.
David Mutryn, Chief Financial Officer of MAXIMUS, Inc. (MMS), reported that on 08/31/2025 he acquired 178.911 dividend equivalent rights that are the economic equivalent of common stock and accrue with previously awarded restricted stock units (RSUs) and certain performance share units (PSUs) whose performance criteria have been met. The reported transaction shows 52,611.789 shares of common stock beneficially owned following the transaction. The filing was signed by an attorney-in-fact on 09/03/2025.
FAQ
What is the current stock price of Maximus (MMS)?
What is the market cap of Maximus (MMS)?
